Evive Biotech is a global biologics company focused on oncology and inflammatory disorders. Developing a portfolio of novel therapies to deliver life-saving treatments for patients worldwide, we are devoted to being the leading Asian biologics company in advancing truly novel biologic products from pre-clinical studies to U.S. BLA submission and commercial launch.
Revolutionary remedies for a healthy and happy world.
Developing innovative medicines for patients worldwide.
What’s Going On
Our innovative assets have recently achieved significant milestones, including the completion of F-627's global Phase III clinical trials, which met its primary and secondary endpoints, the BLA submission of F-627 to the US FDA, and the receipt of orphan drug designation from the US FDA for F-652. We are engaging with potential partners and the broader scientific community to share our successes and to ensure broad access to treatment options for patients.
Evive Biotech Announces Recent Appointments: VP of Biometrics and VP of Clinical Operations
Evive Biotech Announces IND Approval by the NMPA for a Phase II Clinical Study of F-652 in Patients with ACLF
Evive Biotech Announces the Appointment of Dr. Lichuan Liu as Senior VP, Global Head of Clinical and Translational Science
Evive Biotech Announces the Appointment of Dr. Weihai He as Senior VP, Global Head of Business Development
Evive Biotech and Sino Biopharm Subsidiary Announce Strategic Collaboration to Commercialize F-627 in China
Evive Biotech Announces the Appointment of Dr. Liping Sun as Senior VP, Global Head of R&D